Amphastar Pharmaceuticals, Inc.

AMPH · XNAS

CIK 1297184fmd_1Q2P51V1JZEWBXAXE43QNDX7Y5Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	255	240	295	322	350	438	499	644	732	720
Cost of revenue	151	150	188	190	207	238	250	293	358	364
Gross profit	104	91	107	132	143	200	249	351	374	356
Research and development	42	44	58	69	67	61	75	74	74	86
Selling, general and administrative	47	51	58	63	65	69	67	80	95	130
Total operating expenses	89	92	116	132	132	130	141	154	168	216
Operating income	15	(1)	(9)	(0)	11	70	107	197	205	140
Interest expense	1	1	0	0	0	1	2	27	30	25
Interest and investment income	0	0	0	1	1	1	1	5	11	9
Other non-operating income (expense)	(1)	3	(1)	60	(6)	14	9	(26)	(16)	(17)
Income before taxes	15	1	(10)	60	5	84	116	171	190	124
Income tax expense	5	(2)	(3)	14	4	21	23	32	30	26
Net income from continuing operations	10	4	(7)	47	1	64	93	140	160	98
Net income	10	4	(6)	49	1	62	91	138	160	98